The JuggerStitch device is the next generation of this pioneering meniscus repair technology to receive 510(k) clearance and it will now be available to the U.S. market
Image: Zimmer Biomet wins FDA clearance for JuggerStitch. Photo: Courtesy of stockdevil/FreeDigitalPhotos.net
Zimmer Biomet Holdings, a global leader in musculoskeletal healthcare, has announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the JuggerStitch meniscal repair device. The JuggerStitch device is the next generation of this pioneering meniscus repair technology to receive 510(k) clearance and it will now be available to the U.S. market.
“Traditional knotted meniscal fixator repair devices typically use hard plastic anchors and surface knots that can damage cartilage, increasing the risk of complications down the line,” said Keith Lawhorn MD, OrthoVirginia. “The JuggerStitch device offers a less invasive, all-suture, knotless approach to meniscal repair procedures and allows me to improve treatment outcomes for my patients.”
The unique design of the JuggerStitch implant features two soft anchors connected by a knotless, self-locking suture loop. This technology is designed to improve tissue preservation and enhance the surgeon’s control of the tissue compression at the repair site when compared to implants that use a sliding knot to lock the repair.
“Zimmer Biomet is committed to delivering cutting-edge technology and solutions, like the next-generation JuggerStitch meniscal repair device, to help surgeons alleviate pain, restore peak performance and improve the quality of life for patients,” said Dr. Andrew Freiberg, Zimmer Biomet’s Chief Medical Officer. “Our comprehensive sports medicine portfolio provides a variety of options that help patients throughout the care continuum.”
Source: Company Press Release